Jump to content

Choose locationChoose Location
  • Sign in or Enroll
    • Open I want to choose my medical group or hospital
    • Clear my location
Change Location

We've expanded your view

You are now viewing all services in the Sutter Health network. You can change your location above to narrow your view to a medical group, hospital, city or zip.
Sutter Health
  • Video Visits
  • Find Doctors
  • Find Locations
  • Treatments & Services
  • Locations
  • Sign in or Enroll
    • Video Visits
    • Find Doctors
    • Find Locations
    • Treatments & Services
    • COVID-19 Resources
    • Pay a Bill
    • Symptom Checker
    • Get Care Today
    • Diseases & Conditions
    • Health & Wellness
    • Classes & Events
    • Research & Clinical Trials
    • For Patients
    • About Sutter Health
    • Giving
    • Volunteering
    • Careers
    • News
    • For Medical Professionals
    • Other Business Services
Close Search
  • Home
  • Research
  • Investigators
  • Deepti Behl
Content

Investigator Deepti Behl, MD

Deepti Behl, MD

View profile  

Deepti Behl, MD, is a Principal Investigator, medical oncologist and Medical Director of the Sutter Institute for Medical Research (SIMR) in Sacramento.

She also serves as Medical Director, Thoracic Oncology, at the Sutter Medical Center in Sacramento. As a medical oncologist, she specializes in lung cancer, melanoma and head and neck cancers. Dr. Behl leads clinical research and has coauthored peer-reviewed articles and published in high-impact journals such as the Journal of Clinical Oncology (JCO) and Chest.

Dr. Behl is board certified in medical oncology, hematology, and hospice and palliative medicine. She is a member of the Society of Integrative Oncology. She partners with the University of California at Davis as an executive member of the SCOPE committee (Sacramento Citywide Oncology Phase 1 Program). 

Dr. Behl completed residency training in internal medicine and a fellowship in hematology/oncology at the Mayo Clinic, Rochester, MN.



Sutter Health Research Enterprise
2800 L Street, Suite 300
Sacramento, CA, 95816
(916) 453-3300  
simr@sutterhealth.org

Primary Research Interests

  • Breast Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Pancreatic Cancer

Related Clinical Trials

Adjuvant (NRG BR003)

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Investigator: Deepti Behl MD

Status: Active, Recruiting

Locally Advanced (ECOG-ACRIN EA5181)

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Investigator: Deepti Behl MD

Status: Active, Recruiting

Locally Advanced (NRG LU005)

Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer

Investigator: Deepti Behl MD

Status: Active, Recruiting

Locally Advanced (Panova-3)

Randomized, open-label study of TTFields, 150kHz concomitant with gemcitabine and nab-paclitaxel for treatment of locally-advanced pancreatic adenocarcinoma

Investigator: Deepti Behl MD

Status: Active, Recruiting

Locally Advanced (SWOG S1914)

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Investigator: Deepti Behl MD

Status: Active, Recruiting

Locally Advanced (TIGeR-PaC Study)

Multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.

Investigators: Deepti Behl MD, Brian K. Kim M.D, Christopher J Laing M.D., Sivakumar Reddy M.D., Vijay Suhag M.D.

Status: Active, Recruiting

Locally Advanced or Metastatic (NRG GY005) Closed to Accrual

Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primar

Investigator: Deepti Behl MD

Status: Active, Not Recruiting

Locally Advanced or Metastatic (NRG GY009) Temporarily on Hold

Pegylated Liposomal Doxorubicin Hydrochloride W/Atezolizumab and/or Bevacizumab in Treating Patients W/Recurrent Ovarian,Fallopian Tube,or Primary Peritoneal Ca

Investigator: Deepti Behl MD

Status: Active, Not Recruiting

Lung Cancer (AbbVie M14-239)

Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Investigators: Deepti Behl MD, Nitin Rohatgi MD

Status: Active, Recruiting

Lung Cancer (PACIFIC-4 / RTOG-3515)

A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab following stereotactic body radiation therapy (SBRT)

Investigators: Deepti Behl MD, Carlin R Hauck Radiation Oncologist, Christopher Jones MD, Charlotte D Kubicky Radiation Oncologist, Hubert Y Pan Radiation Oncologist, Anthony T Pu Radiation Oncologist, Sivakumar Reddy M.D., Vijay Suhag M.D.

Status: Active, Recruiting

Metastatic (ECOG-ACRIN EA5163/S1709)

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Investigator: Deepti Behl MD

Status: Active, Recruiting

Napoli 3-Ipsen (D-US-60010-001)

Randomized, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine

Investigators: Kristin N. Arreola M.D., Deepti Behl MD, Brian K. Kim M.D, Jasdeepa Nagi M.D., Sivakumar Reddy M.D.

Status: Active, Recruiting

Neoadjuvant (NSABP B-51/ RTOG 1304) Closed to Accrual

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Investigator: Deepti Behl MD

Status: Active, Not Recruiting

Novocure LUNAR

Effect of Tumor Treating Fields Concurrent W/ Standard of Care Therapies for Treatment of Stage 4 NSCLC following Platinum Failure (LUNAR)

Investigators: Deepti Behl MD, Stacy D'Andre MD, Nitin Rohatgi MD, Melissa Williams M.D.

Status: Active, Recruiting

RESILIENT-Ipsen (MM-398-01-03-04)

A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection vs Toptecan in patients with SCLC

Investigators: Kristin N. Arreola M.D., Deepti Behl MD, Rajeswari Chellappah M.D., Brian K. Kim M.D, Jasdeepa Nagi M.D., Sivakumar Reddy M.D., Nitin Rohatgi MD, Vijay Suhag M.D.

Status: Active, Not Recruiting

The Sutter Health Network of Care
Expertise to fit your needs
Primary Care

Check-ups, screenings and sick visits for adults and children.

Specialty Care

Expertise and advanced technologies in all areas of medicine.

Emergency Care

For serious accidents, injuries and conditions that require immediate medical care.

Urgent Care

After-hours, weekend and holiday services.

Walk-In Care

Convenient walk-in care clinics for your non-urgent health needs.

About Sutter

  • About Our Network
  • Annual Report
  • Awards
  • Community Benefit
  • Contact Us
  • News
  • Giving
  • Find Care

  • Birth Centers
  • Care Centers
  • Emergency Rooms
  • Hospitals
  • Imaging
  • Labs
  • Surgery Centers
  • Urgent Care
  • Walk-In Care
  • View All >
  • Featured Services

  • Behavioral Health
  • Cancer Services
  • Family Medicine
  • Home Health and Hospice
  • Orthopedics
  • Pediatrics
  • Pregnancy
  • Primary Care
  • Women's Health
  • View All >
  • Patient Resources

  • Accepted Health Plans
  • Classes and Events
  • Estimate Costs
  • Flu Resources
  • Health and Wellness
  • Medical Records
  • Medicare
  • My Health Online
  • Pay a Bill
  • Symptom Checker
  • Our Team

  • For Employees
  • Physician Careers
  • Recruiting Events
  • Sutter Careers
  • Vendors
  • Volunteers
    • ADA Accessibility
    • Contact
    • Privacy
    • Do Not Sell My Personal Information

    • LinkedIn Opens new window
    • YouTube Opens new window
    • Facebook Opens new window
    • Twitter Opens new window
    • Glassdoor Opens new window
    • Instagram Opens new window

    Copyright © 2021 Sutter Health. All rights reserved. Sutter Health is a registered trademark of Sutter Health ®, Reg. U.S. Patent & Trademark office.

    Cookie Policy

    We use cookies to give you the best possible user experience. By continuing to use the site, you agree to the use of cookies. Privacy Policy Cookie Preferences

    Privacy Policy Cookie Preferences